Cover Image
市場調查報告書

Comvax(B型肝炎病毒(HBV)預防疫苗)- 預測與市場分析

Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298838
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
Comvax(B型肝炎病毒(HBV)預防疫苗)- 預測與市場分析 Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 64 Pages
簡介

B型肝炎是B型肝炎病毒(HBV)所引起的急性或慢性肝炎。全球HBC感染者約20億,HBV相關的肝病造成每年約60萬人的死亡。由於基因重組HBV表面抗原(HBsAg)疫苗大大減輕了過去二十年疾病的負擔,但仍留了成人方面病毒攝取及有效性的疑問。

本報告提供嗜血桿菌B型疫苗(腦膜炎雙球菌蛋白結合體)及重組B型肝炎疫苗(酵母製)的混合疫苗──Merck的Comvax調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 概要
  • 病因·病理生理學
  • 症狀
  • 預測

第4章 疫苗接種宣導與接種率

  • 概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Comvax

  • 概要
  • 免疫抗原性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC333DFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Comvax [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine] is Merck's bivalent combination vaccine that offers protection against infections caused by Hib and all known subtypes of HBV. Comvax contains the antigenic components used in Merck's PedvaxHIB and Recombivax HB vaccines. Upon receiving FDA approval for use in infants six weeks to 15 months of age in 1996, Comvax became the first combination vaccine in the US to protect its recipients against HBV infection. Currently, Comvax is only marketed in the US, as its EU market authorization, under the name Procomvax, was not renewed in 2009.

Scope

  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Comvax including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Comvax for the US from 2012 to 2022.
  • Sales information covered for the US

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Comvax performance
  • Obtain sales forecast for Comvax from 2012-2022 in the US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Comvax

  • 6.1. Overview
  • 6.2. Immunogenicity
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Patient Populations Targeted for Vaccination
    • 7.4.2. Vaccination Coverage Rates
    • 7.4.3. Vaccinated Patients
    • 7.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 7.4.5. General Pricing Assumptions
    • 7.4.6. Individual Vaccine Assumptions
  • 7.5. Physicians and Specialists Included in this Study
    • 7.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 7.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Director
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Product Profile - Comvax
  • Table 9: Immunogenicity Profile - Comvax
  • Table 10: Safety Profile - Comvax
  • Table 11: Comvax SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Comvax, 2012-2022
  • Table 13: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
  • Table 14: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
Back to Top